nach oben

European Journal of Clinical Microbiology & Infectious Diseases

Erschienen in:

18.11.2019 | Original Article

Drug susceptibility patterns of rapidly growing mycobacteria isolated from skin and soft tissue infections in Venezuela

verfasst von: Omaira Da Mata-Jardín, Alejandro Angulo, Margarita Rodríguez, Sandra Fernández-Figueiras, Jacobus H de Waard

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

To our knowledge, this is the first work on drug susceptibility patterns of rapid growing mycobacteria from Latin America. The susceptibility patterns for 14 antimicrobial agents of the three most important species that cause skin infections in Venezuela were determined as follows: 63 strains belonging to Mycobacterium abscessus group, 66 strains of the Mycobacterium fortuitum group, and 13 Mycobacterium chelonae strains. The M. abscessus group strains were resistant to most antibiotics tested while M. fortuitum strains were relatively susceptible to a large number of antibiotics. We demonstrate the presence of an inducible and truncated erm(41) gene in M. abscessus group, namely M. abscessus subsp. massiliense. We show the variations in susceptibility to antimicrobial agents within and between the mycobacterial species and compare our susceptibility patterns with those reported from other countries. We conclude that the identification of mycobacteria to the species level can guide the antibiotic treatment, but that it is always important to consider drug susceptibility testing when rapidly mycobacteria are isolated.

Nur mit Berechtigung zugänglich

Griffiifth D, Aksamit T, Brown-Elliot B, Catanzaro A, Daley C, Gordin F et al (2007) An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175(4):367–416. https://doi.org/10.1164/rccm.200604-571STCrossRef

Song J, Sohn J, Jeong H, Cheong H, Kim W, Kim M (2006) An outbreak of post-acupuncture cutaneous infection due to Mycobacterium abscessus. BMC Infect Dis 6(6):1471–2334. https://doi.org/10.1186/1471-2334-6-6CrossRef

Tang P, Walsh S, Murray C, Alterman C, Varia M, Broukhanski G et al (2006) Outbreak of acupuncture-associated cutaneous Mycobacterium abscessus infections. J Cutan Med Surg 10(4):166–169. https://doi.org/10.2310/7750.2006.00041CrossRefPubMed

Furuya Y, Paéz A, Srinivasan A, Cooksey R, Augenbraun M, Baron M (2008) Outbreak of Mycobacterium abscessus wound infections among “Lipotourists” from the United States Who underwent abdominoplasty in the Dominican Republic. Clin Infect Dis 46(8):1181–1188. https://doi.org/10.1086/529191CrossRefPubMed

Galmés-Truyols A, Giménez-Duran J, Bosch-Isabel C, Nicolau-Riutort A, Vanrell-Berga J, Portell-Arbona M et al (2011) An outbreak of cutaneous infection due to Mycobacterium abscessus associated to mesotherapy. Enferm Infecc Microbiol Clin 29(7):510–514. https://doi.org/10.1016/j.eimc.2011.03.006CrossRefPubMed

Munayco C, Grijalva C, Culqui D, Bolarte J, Suárez-Ognio L, Quispe N et al (2008) Outbreak of persistent cutaneous abscesses due to Mycobacterium chelonae after mesotherapy sessions, Lima, Peru. Rev Saude Publica 42(1):146–149. https://doi.org/10.1590/S0034-89102008000100020CrossRefPubMed

Correa N, Cataño J, Mejía G, Realpe T, Orozco B, Estrada S et al (2010) Outbreak of mesotherapy-associated cutaneous infections caused by Mycobacterium chelonae in Colombia. Jpn J Infect Dis 63(2):143–145PubMed

Carbonne A, Brossier F, Arnaud I, Bougmiza I, Caumes E, Meningaud J et al (2009) Outbreak of nontuberculous mycobacterial subcutaneous infections related to multiple mesotherapy injections. J Clin Microbiol 47(6):1961–1964. https://doi.org/10.1128/JCM.00196-09CrossRefPubMedPubMedCentral

Ivan M, Dancer C, Koehler A, Hobby M, Lease C (2013) Mycobacterium chelonae abscesses associated with biomesotherapy, Australia, 2008. Emerg Infect Dis 19(9):1493–1495. https://doi.org/10.3201/eid1909.120898CrossRefPubMedCentral

10.

Quiñones C, Ramalle-Gómara E, Perucha M, Lezaun M, Fernández-Vilariño E, García-Morrás P et al (2010) An outbreak of Mycobacterium fortuitum cutaneous infection associated with mesotherapy. J Eur Acad Dermatol Venereol 24(5):604–606. https://doi.org/10.1111/j.1468-3083.2009.03461.xCrossRefPubMed

11.

Macadam S, Mehling B, Fanning A, Dufton J, Kowalewska-Grochowska K, Lennox P et al (2007) Nontuberculous mycobacterial breast implant infections. Plast Reconstr Surg 119(1):337–344. https://doi.org/10.1097/01.prs.0000244924.61968.d2CrossRefPubMed

12.

Murillo J, Torres J, Bofill L, Ríos-Fabra A, Irausquin E, Istúriz R et al (2000) Skin and wound infection by rapidly growing mycobacteria: an unexpected complication of liposuction and liposculture. Arch Dermatol 136:1347–1352. https://doi.org/10.1001/archderm.136.11.1347CrossRefPubMed

13.

Piquero J, Casals V, Higuera E, Yakrus M, Sikes D, de Waard J (2004) Iatrogenic Mycobacterium simiae skin infection in an immunocompetent patient. Emerg Infect Dis 10(5):969–970. https://doi.org/10.3201/eid1005.030681CrossRefPubMedPubMedCentral

14.

Cooksey R, de Waard J, Yakrus M, Rivera I, Chopite M, Toney S et al (2004) Mycobacterium cosmeticum sp. nov., a novel rapidly growing species isolated from a cosmetic infection and from a nail salon. Int J Syst Evol Microbiol 54(6):2385–2391. https://doi.org/10.1099/ijs.0.63238-0CrossRefPubMed

15.

Rivera-Olivero I, Guevara A, Escalona A, Oliver M, Perez-Alfonzo R, Piquero J et al (2006) Infecciones en tejidos blandos por micobacterias no tuberculosas secundarias a mesoterapia ¿cuánto vale la belleza? Enferm Infecc Microbiol Clin 24(5):302–306. https://doi.org/10.1157/13089664CrossRefPubMed

16.

Guevara-Patiño A, Sandoval de Mora M, Farreras A, Rivera-Olivero I, Fermin D, de Waard J (2010) Soft tissue infection due to Mycobacterium fortuitum following acupunture: a case report and review of the literature. J Infect Dev Ctries 4(8):521–525. https://doi.org/10.3855/jidc.718CrossRefPubMed

17.

Da Mata-Jardín O, Hernández-Pérez R, Corrales H, Cardoso-Leao S, de Waard J (2010) Follow-up of an outbreak of Mycobacterium abscessus soft-tissue infection associated with mesotherapy in Venezuela. Enferm Infecc Microbiol Clin 28(9):596–501. https://doi.org/10.1016/j.eimc.2009.08.003CrossRefPubMed

18.

Torres-Coy J, Carrera C, Rodríguez-Castillo B, Ramírez-Murga R, Ortiz-Cáceres W, Pérez-Alfonzo R et al (2017) Mycobacterium szulgai: an unusual cause of skin and soft tissue infection after breast augmentation. Int J Dermatol 56(6):e122–e124. https://doi.org/10.1111/ijd.13605CrossRefPubMed

19.

Ruiz-Aragón J, García-Agudo L, Flores S, Rodríguez M, Marín P, García-Martos P (2007) Susceptibilty to antimicrobial agents of rapidly growing mycobacteria. Rev Esp Quimioterap 20(4):429–432

20.

García-Agudo L, García-Martos P, Jesús I, Rodríguez-Iglesias M (2009) Assesment of in vitro susceptibility to antimicrobials of rapidly growing mycobacteria by E-test. Rev Med Chil 137(7):912–917CrossRef

21.

Hatakeyama S, Ohama Y, Okazaki M, Nukui Y, Moriya K (2017) Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan. BMC Infect Dis 17(1):197. https://doi.org/10.1186/s12879-017-2298-8CrossRefPubMedPubMedCentral

22.

Pang H, Li G, Zhao X, Liu H, Wan K, Yu P (2015) Drug susceptibility testing of 31 antimicrobial agents on rapidly growing mycobacteria isolates from China. Biomed Res Int 2015:419392. https://doi.org/10.1155/2015/419392CrossRefPubMedPubMedCentral

23.

Park S, Kim S, Park E, Kim H, Kwon O, Chang C et al (2008) In vitro antimicrobial susceptibility of Mycobacterium abscessus in Korea. J Korean Med Sci 23(1):49–52. https://doi.org/10.3346/jkms.2008.23.1.49CrossRefPubMedPubMedCentral

24.

Yang S, Hsueh P, Lai H, Teng L, Huang L, Chen J et al (2003) High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother 47(6):1958–1962. https://doi.org/10.1128/AAC.47.6.1958-1962.2003CrossRefPubMedPubMedCentral

25.

Huang Y, Liu M, Shen G, Lin C, Kao C, Liu P et al (2010) Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing. J Microbiol Immunol Infect 43(5):401–406. https://doi.org/10.1016/S1684-1182(10)60063-1CrossRefPubMed

26.

Lee S, Kim J, Jeong J, Park Y, Bai G, Lee E et al (2007) Evaluation of the broth microdilution method using 2,3-diphenyl-5-thienyl-(2)-tetrazolium chloride for rapidly growing mycobacteria susceptibility testing. J Korean Med 22(5):784–790. https://doi.org/10.3346/jkms.2007.22.5.784CrossRef

27.

Heidarieh P, Mirsaeidi M, Hashemzadeh M, Feizabadi M, Bostanabad S, Nobar M et al (2016) In vitro antimicrobial susceptibility of nontuberculous mycobacteria in Iran. Microb Drug Resist 22(2):172–178. https://doi.org/10.1089/mdr.2015.0134CrossRefPubMed

28.

Tang S, Lye D, Jureen R, Sng L, Hsu L (2015) Rapidly growing mycobacteria in Singapore, 2006-2011. Clin Microbiol Infect 21(3):236–241. https://doi.org/10.1016/j.cmi.2014.10.018CrossRefPubMed

29.

Lee S, Yoo H, Kim S, Koh W, Kim C, Park Y et al (2014) The drug resistance profile of Mycobacterium abscessus group strains from Korea. Ann Lab Med 34(1):31–37. https://doi.org/10.3343/alm.2014.34.1.31CrossRefPubMed

30.

Wallace RJ, Brown-Elliott B, Ward S, Crist C, Mann L, Wilson R (2001) Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 45(3):764–767. https://doi.org/10.1128/AAC.45.3.764-767.2001CrossRefPubMedPubMedCentral

31.

Telenti A, Marchesi F, Balz M, Bally F, Böttger E, Bodmer T (1993) Rapid identification of mycobacteria to the species level by polymerase chain reaction and restriction enzyme analysis. J Clin Microbiol 31(2):175–178CrossRef

32.

da Costa A, Lopes M, Furlaneto I, de Sousa M, Lima K (2010) Molecular identification of nontuberculous mycobacteria isolates in a Brazilian mycobacteria reference laboratory. Diagn Microbiol Infect Dis 68(4):390–394. https://doi.org/10.1016/j.diagmicrobio.2010.07.019CrossRefPubMed

33.

Nash K, Brown-Elliott B, Wallace RJ (2009) A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 53(4):1367–1376. https://doi.org/10.1128/AAC.01275-08CrossRefPubMedPubMedCentral

34.

Wallace RJ, Brown-Elliott B, Wilson R, Mann L, Hall L, Zhang Y et al (2004) Clinical and laboratory features of Mycobacterium porcinum. J Clin Microbiol 42(12):5689–5697. https://doi.org/10.1128/JCM.42.12.5689-5697.2004CrossRefPubMedPubMedCentral

35.

Woods GL, Browm-Elliot BA, Conville PS et al (2011) Susceptibility Testing of Mycobacteria, Nocardiae, and other aerobic actinomycetes; Approved Standard- Second edition, CLSI document M24-A2. Clinical and Laboratory Standards Institute (CLSI), Wayne ISBN 1-56238-746-4, ISSN 0273-3099

36.

Wallace RJ, Brown-Elliot B, Crist C, Mann L, Wilson R (2002) Comparison of the in vitro activity of the glycylcline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother 46(10):3164–3167. https://doi.org/10.1128/AAC.46.10.3164-3167.2002CrossRefPubMed

37.

Huang C, Wu M, Chen H, Huang W (2018) In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates. J Microbiol Immunol Infect 51(5):636–643. https://doi.org/10.1016/j.jmii.2017.05.001CrossRefPubMed

38.

Kim H, Kim B, Kook Y, Yun Y, Shin J, Kim B et al (2010) Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patterns. Microbiol Immunol 54(6):347–353. https://doi.org/10.1111/j.1348-0421.2010.00221.xCrossRefPubMed

39.

Bastian S, Veziris N, Roux A, Brossier F, Gaillard J, Jarlier V et al (2011) Assessment of clarithromycin susceptibility in strains belonging to the Mycobacteium abscessus group by erm(41) and rrl sequencing. Antimicrob Agents Chemother 55(2):775–781. https://doi.org/10.1128/AAC.00861-10CrossRefPubMed

40.

De Groote M, Huitt G (2006) Infections due to rapidly growing mycobacteria. Clin Infect Dis 42(12):1756–1763. https://doi.org/10.1086/504381CrossRefPubMed

41.

Hwang T, Dotsenko S, Jafarov A, Weyer K, Falzon D, Lunte K et al (2014) Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resisitant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. BMJ Open 4(1):e004143. https://doi.org/10.1136/bmjopen-2013-004143CrossRefPubMedPubMedCentral

42.

Wallace RJ, Dukart G, Brown-Elliott B, Griffith D, Scerpella E, Marshall B (2014) Clinical experience in 52 patients witth tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. J Antimicrob Chemother 69(7):1945–1953. https://doi.org/10.1093/jac/dku062CrossRefPubMedPubMedCentral

43.

Nie W, Duan H, Huang H, Lu Y, Chu N (2015) Species identification and clarithromycin susceptibility testing of 278 clinical nontuberculous mycobacteria isolates. Biomed Res Int 2015:506598. https://doi.org/10.1155/2015/506598CrossRefPubMedPubMedCentral

44.

Christianson S, Grierson W, Kein D, Tyler A, Wolfe J, Sharma M (2016) Time to detection of inducible macrolide resistance in Mycobacterium abscessus subspecies and its association with the Erm(41) sequevar. PLoS One 11(8):e0158723. https://doi.org/10.1371/journal.pone.0158723CrossRefPubMedPubMedCentral

45.

Li B, Yang S, Chu H, Zhang Z, Liu W, Luo L et al (2017) Relationship between antibiotic susceptibility and genotype in Mycobacterium abscessus clinical isolates. Front Microbiol 14(8):1739. https://doi.org/10.3389/fmicb.2017.01739CrossRef

46.

Rubio M, March F, Garrigó M, Moreno C, Español M, Coll P (2015) Inducible and acquired clarithromycin resistance in the Mycobacterium abscessus complex. PLoS One 10(10):e0140166. https://doi.org/10.1371/journal.pone.0140166CrossRefPubMedPubMedCentral

47.

Hanson K, Slechta E, Muir H, Barker A (2014) Rapid molecular detection of inducible macrolide resistance in Mycobacterium chelonae and M. abscessus strains: a replacement for 14 day susceptibility testing? J Clin Microbiol 52(5):1705–1707. https://doi.org/10.1128/JCM.03464-13CrossRefPubMedPubMedCentral

48.

Esteban J, Martín-de-Hijas N, García-Almeida D, Bodas-Sánchez A, Gadea I, Fernández-Roblas R (2009) Prevalence of erm methylase genes in clinical isolates of non-pigmented, rapidly growing mycobacteria. Clin Microbiol Infect 15(10):919–923. https://doi.org/10.1111/j.1469-0691.2009.02757.xCrossRefPubMed

49.

Ali S, Khan F, Fisher M (2007) Catheter-related bloodstream infection caused by Mycobacterium mageritense. J Clin Microbiol 45(1):273. https://doi.org/10.1128/JCM.01224-06CrossRefPubMed

50.

Gira A, Reisenauer A, Hammock L, Nadiminti U, Macy J, Reeves A et al (2004) Furunculosis due to Mycobacterium mageritense associated with footbaths at a nail salon. J Clin Microbiol 42(4):1813–1817. https://doi.org/10.1128/JCM.42.4.1813-1817.2004CrossRefPubMedPubMedCentral

51.

Wallace RJ, Brown-Elliot B, Hall L, Roberts G, Wilson R, Mann L et al (2002) Clinical and laboratory features of Mycobacterium mageritense. J Clin Microbiol 40(8):2930–2935. https://doi.org/10.1128/JCM.40.8.2930-2935.2002CrossRefPubMed

52.

Fernández-Roblas R, Martín-de-Hijas N, Fernández-Martínez A, García-Almeida D, Gadea I, Esteban J (2008) In vitro activities of tigecycline and 10 other antimicrobials against nonpigmented rapidly growing mycobacteria. Antimicrob Agents Chemother 52(11):4184–4186. https://doi.org/10.1128/AAC.00695-08CrossRefPubMedPubMedCentral

Titel: Drug susceptibility patterns of rapidly growing mycobacteria isolated from skin and soft tissue infections in Venezuela
verfasst von: Omaira Da Mata-Jardín
Alejandro Angulo
Margarita Rodríguez
Sandra Fernández-Figueiras
Jacobus H de Waard
Publikationsdatum: 18.11.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 3/2020
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-019-03740-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Drug susceptibility patterns of rapidly growing mycobacteria isolated from skin and soft tissue infections in Venezuela

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Development of immunochromatographic device as a point-of-care tool for serodiagnosis of human strongyloidiasis cases

Recurrent community-acquired Clostridium(Clostridioides)difficile infection in Serbianchildren

Evaluation of serological diagnostic tests of human brucellosis for prevention and control in Mexico

Levels of human cytomegalovirus miR-US25-1-5p and miR-UL112-3p in serum extracellular vesicles from infants with HCMV active infection are significantly correlated with liver damage

Impact of thrombocytes, on bacterial growth and antimicrobial activity of selected antibiotics

Assessment of VITEK® MS IVD database V3.0 for identification of Nocardia spp. using two culture media and comparing direct smear and protein extraction procedures

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin